摘要
目的:探究生脉胶囊辅助治疗对慢性阻塞性肺疾病(COPD)合并肺源性心脏病患者心肺功能、全血黏度及不良事件的影响。方法:以桐乡市第四人民医院的100例COPD伴肺心病患者为研究对象,以随机数字表法分为对照组和研究组(各50例),对照组接受利尿、化痰、抗感染、吸氧等常规治疗,研究组在对照组基础上服用生脉胶囊,均干预治疗1个月,随访3个月。对比疗效以及治疗前后不同时间点的右室收缩压(RVSP)、肺动脉收缩压(PASP)、左室射血分数(LVEF)、用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC、全血黏度和纤维蛋白原;对比两组随访3个月后的累积不良事件发生率。结果:相比于对照组,研究组的总有效率更高,差异有统计学意义(P<0.05);对比治疗前,两组治疗后的RVSP均降低且LVEF、PASP均增高,对比对照组治疗后数据,研究组的RVSP更低且PASP、LVEF更高(均P<0.05);对比治疗前,两组治疗后的FVC、FEV_(1)和FEV_(1)/FVC均增高,且研究组的3项指标更高,组间比较差异均有统计学意义(均P<0.05);对比治疗前,两组治疗后全血黏度和纤维蛋白原更低,且研究组2项指标的数值更低,组间比较差异有统计学意义(均P<0.05);对照组累积不良事件发生率为26.00%(13/50),显著高于研究组的6.00%(3/50)(P<0.05)。结论:COPD合并肺源性心脏病患者应用生脉胶囊辅助治疗可显著提升临床治疗效果,改善患者的心肺功能和全血黏度,降低累积不良事件发生率,临床疗效和安全性较高。
Objective:To explore the effects of Shengmai capsule adjuvant therapy on cardiopulmonary function,whole blood viscosity and adverse events in patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary heart disease.Methods:In this study,100 patients with COPD and pulmonary heart disease in the Fourth People’s Hospital of Tongxiang were randomized into the control group and study group with 50 in each group.The patients in the control group received conventional treatment including diuresis,resolving phlegm,anti-infection and oxygen inhalation,etc,and those in the study group took Shengmai capsule on the basis of the control group for 1 month and followed up for 3 months.Comparison of RVSP,PASP,LVEF,FVC,FEV_(1),FEV_(1)/FVC,whole blood viscosity and fibrinogen at different time points before and after the treatment was conducted between the 2 goups.Meanwhile,the cumulative incidence of adverse events after 3 months of follow-up was compared between the 2 groups.Results:Compared with the control group,the total effective rate of the study group was significantly higher(P<0.05).RVSP was decreased and LVEF and PASP were increased in both groups after treatment.Compared with the control group after treatment,RVSP was lower and PASP and LVEF were higher in the study group(P<0.05).FVC,FEV_(1) and FEV_(1)/FVC were increased and the team’s three indicators had a higher value after treament in both groups(P<0.05).The two groups had lower whole blood viscosity and fibrinogen after treatment and comparison showed that these 2 indexes were significantly lower in the study group than in the control(P<0.05).The cumulative incidence of adverse events in the control group was 26.00%(13/50),which was significantly higher than 6.00%(3/50)of the study group(P<0.05).Conclusion:The application of Shengmai capsule in the adjuvant treatment of COPD patients with pulmonary heart disease can significantly improve the clinical treatment effect of patients,improve the cardiopulmonary function index and whole blood viscosity,reduce the incidence of cumulative adverse events.So it has high clinical efficacy and safety.
作者
吴迪
严晓英
杨海波
陈伟翔
陈伟
WU Di;YAN Xiao-ying;YANG Hai-bo;CHEN Wei-xiang;CHEN Wei(Department of Emergency,the Fourth People’s Hospital of Tongxiang,Tongxiang 314502,China;Department of Emergency,the Second Hospital of Jiaxing,Jiaxing 314001,China)
出处
《中国药物应用与监测》
CAS
2023年第4期231-235,共5页
Chinese Journal of Drug Application and Monitoring
基金
桐乡市科技计划基金项目(202202352)。
关键词
慢性阻塞性肺疾病
肺源性心脏病
生脉胶囊
心肺功能
全血黏度
不良事件
Chronic obstructive pulmonary disease
Pulmonary heart disease
Shengmai capsule
Cardiopulmonary function
Whole blood viscosity
Adverse event
作者简介
吴迪,男,主治中医师,研究方向:心脏冠状动脉疾病。E-mail:15967365767@163.com。
